Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma - Hong, D. S., Moore, K., Patel, M., Grant, S. C., Burris, H. A., William, W. N., Jones, S., Meric-Bernstam, F., Infante, J., Golden, L., Zhang, W., Martinez, R., Wijayawardana, S., Beckmann, R., Lin, A. B., Eng, C., Bendell, J. (The American Association for Cancer Research (AACR), 2018)
6304540